“They can inhibit VEGF formation (as used in cerebral oedema dexamethason, or barbiturates, trichstatin A, candesartan , small molecule inhibitors of hypoxia-inducible factor 1, gelandamycin, antysenses, rybosymes and catechins ) or VEGF activity (soluble receptors, monoclonal antibodies, heterodimeric antagonistic VEGF variant, RTK inhibitors and catechins).”